QIAGEN Acquires Genoox for $70 Million to Enhance Clinical Genomics Portfolio with AI-Powered Platform

Reuters

05-13

QIAGEN Acquires Genoox for $70 Million to Enhance Clinical Genomics Portfolio with AI-Powered Platform

QIAGEN NV has announced the acquisition of Genoox, a provider of AI-powered software for clinical genomics, for $70 million in cash, with additional milestone payments of up to $10 million. This strategic move enhances QIAGEN's clinical genomics portfolio, adding the Franklin solution, an AI-powered cloud platform for clinical decision support in genetic diseases. The acquisition strengthens QIAGEN's Digital Insights offering, particularly for small and mid-sized labs worldwide, by providing an easy-to-use, fast, and flexible tool for NGS data interpretation. Franklin complements existing QIAGEN solutions such as QCI Interpret, QCI Precision Insights, and the company's genetic databases, COSMIC and HGMD. The transaction is expected to generate approximately $5 million in sales for QIAGEN by 2025 and is anticipated to have a neutral impact on adjusted EPS.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief via Business Wire (Ref. ID: 20250512358698) on May 12, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2535078941"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535078941\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2535078941?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-13 04:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535078941","market":"nz","top_or_hot":-1,"title":"QIAGEN Acquires Genoox for $70 Million to Enhance Clinical Genomics Portfolio with AI-Powered Platform","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      QIAGEN Acquires Genoox for $70 Million to Enhance Clinical Genomics Portfolio with AI-Powered Platform\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        QIAGEN NV has announced the acquisition of Genoox, a provider of AI-powered software for clinical genomics, for $70 million in cash, with additional milestone payments of up to $10 million. This strategic move enhances QIAGEN's clinical genomics portfolio, adding the Franklin solution, an AI-powered cloud platform for clinical decision support in genetic diseases. The acquisition strengthens QIAGEN's Digital Insights offering, particularly for small and mid-sized labs worldwide, by providing an easy-to-use, fast, and flexible tool for NGS data interpretation. Franklin complements existing QIAGEN solutions such as QCI Interpret, QCI Precision Insights, and the company's genetic databases, COSMIC and HGMD. The transaction is expected to generate approximately $5 million in sales for QIAGEN by 2025 and is anticipated to have a neutral impact on adjusted EPS.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief via Business Wire (Ref. ID: 20250512358698) on May 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>QIAGEN Acquires Genoox for $70 Million to Enhance Clinical Genomics Portfolio with AI-Powered Platform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQIAGEN Acquires Genoox for $70 Million to Enhance Clinical Genomics Portfolio with AI-Powered Platform\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-13 04:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      QIAGEN Acquires Genoox for $70 Million to Enhance Clinical Genomics Portfolio with AI-Powered Platform\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        QIAGEN NV has announced the acquisition of Genoox, a provider of AI-powered software for clinical genomics, for $70 million in cash, with additional milestone payments of up to $10 million. This strategic move enhances QIAGEN's clinical genomics portfolio, adding the Franklin solution, an AI-powered cloud platform for clinical decision support in genetic diseases. The acquisition strengthens QIAGEN's Digital Insights offering, particularly for small and mid-sized labs worldwide, by providing an easy-to-use, fast, and flexible tool for NGS data interpretation. Franklin complements existing QIAGEN solutions such as QCI Interpret, QCI Precision Insights, and the company's genetic databases, COSMIC and HGMD. The transaction is expected to generate approximately $5 million in sales for QIAGEN by 2025 and is anticipated to have a neutral impact on adjusted EPS.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief via Business Wire (Ref. ID: 20250512358698) on May 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2125909593.SGD","symbol_name":"Natixis Thematics Meta R/A SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250512:nNDL3FPyQL:1","article_id":"2535078941","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535078941","pubTimestamp":1747080336,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"QIAGEN NV has announced the acquisition of Genoox, a provider of AI-powered software for clinical genomics, for $70 million in cash, with additional milestone payments of up to $10 million. This strategic move enhances QIAGEN's clinical genomics portfolio, adding the Franklin solution, an AI-powered cloud platform for clinical decision support in genetic diseases. The acquisition strengthens QIAGEN's Digital Insights offering, particularly for small and mid-sized labs worldwide, by providing an easy-to-use, fast, and flexible tool for NGS data interpretation. Franklin complements existing QIAGEN solutions such as QCI Interpret, QCI Precision Insights, and the company's genetic databases, COSMIC and HGMD. The transaction is expected to generate approximately $5 million in sales for QIAGEN by 2025 and is anticipated to have a neutral impact on adjusted EPS.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","LU1923622614.USD":"Natixis Thematics Meta R/A USD","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","BK4121":"生命科学工具和服务","QGEN":"快而精医药","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD"},"translate_title":"QIAGEN以7000万美元收购Genoox，通过人工智能平台增强临床基因组学产品组合","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QGEN":0.9},"content_text":"QIAGEN Acquires Genoox for $70 Million to Enhance Clinical Genomics Portfolio with AI-Powered Platform\n    \n\n        QIAGEN NV has announced the acquisition of Genoox, a provider of AI-powered software for clinical genomics, for $70 million in cash, with additional milestone payments of up to $10 million. This strategic move enhances QIAGEN's clinical genomics portfolio, adding the Franklin solution, an AI-powered cloud platform for clinical decision support in genetic diseases. The acquisition strengthens QIAGEN's Digital Insights offering, particularly for small and mid-sized labs worldwide, by providing an easy-to-use, fast, and flexible tool for NGS data interpretation. Franklin complements existing QIAGEN solutions such as QCI Interpret, QCI Precision Insights, and the company's genetic databases, COSMIC and HGMD. The transaction is expected to generate approximately $5 million in sales for QIAGEN by 2025 and is anticipated to have a neutral impact on adjusted EPS.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief via Business Wire (Ref. ID: 20250512358698) on May 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}